Terms: = Leukemia AND HER1, YOR227W AND Treatment
3 results:
1. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract] [Full Text] [Related]
2. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Bose P; Ozer H
Expert Opin Investig Drugs; 2009 Nov; 18(11):1735-51. PubMed ID: 19780706
[TBL] [Abstract] [Full Text] [Related]
3. Targeted cancer therapies.
Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
[TBL] [Abstract] [Full Text] [Related]
